Monday 17 February 2020 ,
Monday 17 February 2020 ,
Latest News
  • China urges Bangladesh not to go for other countries
  • Mobile radiation is not harmful to health: BTRC
  • Prothom Alo Editor granted bail over Abrar’s death instance
  • One dead, Seven wounded in Narayanganj fire
  • Coronavirus death toll jumps to 1,770
  • Shun mindset of running after jobs: PM
  • Chinese, local suspects hospitalised in two dists
27 January, 2020 00:00 00 AM / LAST MODIFIED: 26 January, 2020 11:02:01 PM

FDA approves Ozempic (semaglutide) for cardiovascular risk reduction in adults with Type 2 Diabetes and known heart disease

drugs.com
FDA approves Ozempic (semaglutide) for cardiovascular risk reduction in adults with Type 2 Diabetes and known heart disease

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic (semaglutide) injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease.

Additional details were added to the Rybelsus (semaglutide) tablets 7 mg or 14 mg Prescribing Information about the primary analysis for PIONEER 6.

Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes. Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.

The FDA's decision on Ozempic is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT) which examined the cardiovascular safety of adding Ozempic or placebo to standard of care in adults with type 2 diabetes and established cardiovascular disease. In the 2-year SUSTAIN 6 trial, Ozempic significantly reduced the risk of the occurrence of a three-component MACE endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The estimated relative risk reduction of MACE was 26% vs placebo (HR 0.74 [95% CI: 0.58, 0.95], p<0.001 for noninferiority, median observation time 2.1 years) with the primary composite outcome occurring in 6.6% of patients treated with Ozempic® vs 8.9% with placebo.

During the trial, gastrointestinal adverse events were more frequent in the Ozempic® group than in the placebo group. The majority of gastrointestinal adverse events occurred during the first 30 weeks.

"There is a well-established link between cardiovascular disease and type 2 diabetes. It's one of our biggest concerns with type 2 diabetes because even when patients reach their blood sugar targets, the risk of a major adverse CV event remains," said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk.

"Today's milestone establishes Ozempic® as an option for patients to help address two critical aspects of managing type 2 diabetes, blood sugar control and cardiovascular risk reduction, in those with known heart disease."

The Rybelsus prescribing information has been updated in section 14 (clinical studies) to include an analysis from the primary endpoint of the PIONEER 6 CVOT showing the hazard ratio for time to first three-component MACE (HR 0.79 [95% CI: 0.57, 1.11]).

In June 2019, Novo Nordisk initiated the SOUL CVOT in 9,642 adults with type 2 diabetes and established cardiovascular disease to further evaluate the cardiovascular effect of Rybelsus. The trial is investigating the effects of Rybelsus on the incidence of MACE vs placebo in addition to standard of care.

About the SUSTAIN 6 Trial

SUSTAIN 6 was an event- and time-driven, pre-approval CVOT for Ozempic®. It was a randomized, double-blinded, noninferiority placebo-controlled trial evaluating the cardiovascular safety of Ozempic® vs placebo when added to standard of care in 3,297 adults with type 2 diabetes with established CVD for a minimum observation period of two years.

=

 

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Liver or Hepar is a wedge shaped solid but soft friable gland in right upper quadrant of the abdomen which weighs 1600g in males and 1300g in females.…
Liver diseases: What you should know

Liver diseases: What you should know

Your liver does a lot of things that keep you healthy. It turns nutrients into chemicals your body needs. It filters out poisons. It helps turn food into…
Liver abscess

Liver abscess

Liver abscess is a pus-filled cyst in the liver. The liver is an organ in the digestive system that assists the digestive process and carries out many…
An overview of liver cancer

An overview of liver cancer

LISA FAYED Liver cancer is uncommon in the United States but is common worldwide due to risk factors such as chronic hepatitis B and hepatitis C infections…
Cirrhosis management

Cirrhosis management

Cirrhosis is a potentially life-threatening condition that occurs when inflammation and scarring damage the liver. No treatment will cure cirrhosis or…
Brain cells long thought of as passive play key role in memory – study in mice

Brain cells long thought of as passive play key role in memory – study in mice

Microglia are resident immune cells in your brain that act as first responders, always on the lookout for trouble. Accounting for about 10% of our brain…
A low-sulfur diet could help you live longer, and eating less meat could be the key

A low-sulfur diet could help you live longer, and eating less meat could be the key

Consuming too much of a certain amino acid, found in animal protein, has been linked to a variety of age-related chronic illness, according to new research.…
Are coronavirus tests flawed?

Are coronavirus tests flawed?

JAMES GALLAGHER  There are deep concerns laboratory tests are incorrectly telling people they are free of the coronavirus. Stories in several countries…
FDA requests withdrawal of weight-loss drug

FDA requests withdrawal of weight-loss drug

Issue: FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because…
Common drugs might help prevent death from a 'broken heart'

Common drugs might help prevent death from a 'broken heart'

When someone close to you dies, grief can literally break your heart, but two common medicines may help prevent a heart attack. "While almost everyone…
FDA approves Audenz (Influenza A (H5N1) Monovalent vaccine

FDA approves Audenz (Influenza A (H5N1) Monovalent vaccine

Seqirus, a global leader in influenza prevention and pandemic response, recently announced that the U.S. Food and Drug Administration (FDA) has approved…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting